References
- Bachmayr-Heyda A, Aust S, Heinze G, et al (2013). Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients--a study of the OVCAD consortium. BMC Cancer, 13, 422. https://doi.org/10.1186/1471-2407-13-422
- Bian J, Li B, Kou XJ, et al (2014). Clinical applicability of multi-tumor marker protein chips for diagnosing ovarian cancer. Asian Pac J Cancer Prev, 15, 8409-11. https://doi.org/10.7314/APJCP.2014.15.19.8409
- Heintz AP, Odicino F, Maisonneuve P, et al (2006). Carcinoma of the ovary. FIGO 26th Annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet, 95, 161-92. https://doi.org/10.1016/j.ijgo.2006.05.005
- Clarke B, Tinker AV, Lee CH, et al (2009). Intraepithelial T cells and prognosis in ovarian carcinoma, novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol, 22, 393-402. https://doi.org/10.1038/modpathol.2008.191
- Clemente CG, Mihm MC Jr, Bufalino R, et al (1996). Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer, 77, 1303-10. https://doi.org/10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5
- deLeeuw RJ, Kroeger DR, Kost SE, et al (2014). CD25 identifies a subset of CD4+FoxP3-TIL that are exhausted yet prognostically favorable in human ovarian cancer. Cancer Immunol Res, 2014.
- Gasparri ML, Bellati F, Napoletano C, et al (2013). Interaction between Treg cells and angiogenesis, a dark double track. Int J Cancer, 132, 2469. https://doi.org/10.1002/ijc.27920
- Giannakakis A, Karapetsas A, Dangaj D, et al (2014). Overexpression of SMARCE1 is associated with CD8+ T-cell infiltration in early stage ovarian cancer. Int J Biochem Cell Biol, 53, 389-98. https://doi.org/10.1016/j.biocel.2014.05.031
- Guo CL, Yang HC, Yang XH, et al (2012). Associations between infiltrating lymphocyte subsets and hepatocellular carcinoma. Asian Pac J Cancer Prev, 13, 5909-13. https://doi.org/10.7314/APJCP.2012.13.11.5909
- Hwang WT1, Adams SF, Tahirovic E, et al (2012). Prognostic significance of tumor-infiltrating T cells in ovarian cancer, a meta-analysis. Gynecol Oncol, 124, 192-8. https://doi.org/10.1016/j.ygyno.2011.09.039
- Jochems C1, Schlom J (2011). Tumor-infiltrating immune cells and prognosis, the potential link between conventional cancer therapy and immunity. Exp Biol Med, 236, 567-79. https://doi.org/10.1258/ebm.2011.011007
- Kroemer G1, Galluzzi L, Kepp O, et al (2013). Immunogenic cell death in cancer therapy. Annu Rev Immunol, 31, 51-72. https://doi.org/10.1146/annurev-immunol-032712-100008
- Leone Roberti Maggiore U, Bellati F, Ruscito I, Gasparri ML, et al (2013). Monoclonal antibodies therapies for ovarian cancer. Expert Opin Biol Ther, 13, 739-64. https://doi.org/10.1517/14712598.2013.767328
- Luo L, Dong LY, Yan QG. (2014) Research Progress in Applying Proteomics Technology to Explore Early Diagnosis Biomarkers of Breast Cancer, Lung Cancer and Ovarian Cancer. Asian Pac J Cancer Prev, 15, 8529-38. https://doi.org/10.7314/APJCP.2014.15.20.8529
- Marchetti C, Imperiale L, Gasparri ML, et al (2012). Olaparib, PARP1 inhibitor in ovarian cancer. Expert Opin Investig Drugs, 21, 1575-84. https://doi.org/10.1517/13543784.2012.707189
- Mougiakakos D, Choudhury A, Lladser A, et al (2010). Regulatory T cells in cancer. Adv Cancer Res, 107, 57-117. https://doi.org/10.1016/S0065-230X(10)07003-X
- Napoletano C, Bellati F, Landi R, et al (2010). Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression. J Cell Mol Med, 14, 2748-59. https://doi.org/10.1111/j.1582-4934.2009.00911.x
- Nielsen JS, Sahota RA, Milne K, et al (2012). CD20+ tumorinfiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin Cancer Res, 18, 3281-92. https://doi.org/10.1158/1078-0432.CCR-12-0234
- Papadia A, Morotti M. (2013). Diaphragmatic surgery during cytoreduction for primary or recurrent epithelial ovarian cancer, a review of the literature. Arch Gynecol Obstet, 287, 733-41. https://doi.org/10.1007/s00404-013-2715-1
- Paroli M, Bellati F, Videtta M, et al (2014). Discovery of chemotherapy-associated ovarian cancer antigens by interrogating memory T cells. Int J Cancer, 134, 1823-34. https://doi.org/10.1002/ijc.28515
- Paulson KG, Carter JJ, Johnson LG, et al (2010).Antibodies to merkel cell polyomavirus T antigen oncoproteins reflect tumor burden in merkel cell carcinoma patients. Cancer Res, 70, 8388-97. https://doi.org/10.1158/0008-5472.CAN-10-2128
- Raspollini MR, Castiglione F, Rossi Degl'innocenti D, et al (2005). Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma. Ann Oncol, 16, 590-6. https://doi.org/10.1093/annonc/mdi112
- Salama M, Ormonde D, Quach T, et al (2010). Outcomes of endoscopic resection of large colorectal neoplasms, an Australian experience. J Gastroenterol Hepatol, 25, 84-9. https://doi.org/10.1111/j.1440-1746.2009.05987.x
- Santegoets SJ, Turksma AW, Suhoski MM, et al (2013). IL-21 promotes the expansion of CD27+ CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells. J Transl Med, 11, 37. https://doi.org/10.1186/1479-5876-11-37
- Sato E, Olson SH, Ahn J, et al (2005). Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A, 102, 18538-43. https://doi.org/10.1073/pnas.0509182102
- Schreiber RD, Old LJ, Smyth MJ et al (2011). Cancer immunoediting, integrating immunity's roles in cancer suppression and promotion. Science, 331, 1565-70. https://doi.org/10.1126/science.1203486
- Tomsova M, Melichar B, Sedlakova I, et al (2008). Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecol Oncol, 108, 415-20. https://doi.org/10.1016/j.ygyno.2007.10.016
- Webb JR, Milne K, Watson P, et al (2014). Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer. Clin Cancer Res, 20, 434-44. https://doi.org/10.1158/1078-0432.CCR-13-1877
- Yigit R, Massuger LF, Figdor CG, et al (2010). Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gynecol Oncol, 117, 366-72. https://doi.org/10.1016/j.ygyno.2010.01.019
- Zhang L, Conejo-Garcia JR, Katsaros D, et al (2003). Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med, 348, 203-13. https://doi.org/10.1056/NEJMoa020177
- Zitvogel L, Kepp O, Kroemer G. (2011) Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol, 8, 151-60. https://doi.org/10.1038/nrclinonc.2010.223
Cited by
- Evaluation of Effects of Metformin in Primary Ovarian Cancer Cells vol.16, pp.16, 2015, https://doi.org/10.7314/APJCP.2015.16.16.6973
- CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer vol.115, pp.5, 2016, https://doi.org/10.1038/bjc.2016.172
- Conservation of immune gene signatures in solid tumors and prognostic implications vol.16, pp.1, 2016, https://doi.org/10.1186/s12885-016-2948-z
- Circulating tumor cells as trigger to hematogenous spreads and potential biomarkers to predict the prognosis in ovarian cancer vol.37, pp.1, 2016, https://doi.org/10.1007/s13277-015-4299-9
- Bone marrow T-cell percentage: A novel prognostic indicator in acute myeloid leukemia vol.105, pp.4, 2017, https://doi.org/10.1007/s12185-016-2153-5
- Elevated serum interleukin-37 level is a predictive biomarker of poor prognosis in epithelial ovarian cancer patients vol.295, pp.2, 2017, https://doi.org/10.1007/s00404-016-4258-8
- Beyond circulating microRNA biomarkers: Urinary microRNAs in ovarian and breast cancer vol.39, pp.5, 2017, https://doi.org/10.1177/1010428317695525
- Tumor microenvironmental factors have prognostic significances in advanced gastric cancer vol.126, pp.10, 2018, https://doi.org/10.1111/apm.12889
- The predictive value and role of stromal tumor-infiltrating lymphocytes in pancreatic ductal adenocarcinoma (PDAC) vol.19, pp.4, 2018, https://doi.org/10.1080/15384047.2017.1416932
- Immunotherapy in endometrial cancer: new scenarios on the horizon vol.30, pp.2005-0399, 2019, https://doi.org/10.3802/jgo.2019.30.e46